OREANDA-NEWS. March 27, 2015. Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced it has secured equity funding of more than \\$20 million from new and all of Selecta’s existing investors.

“With strong financial support from both our current and new investors, we are now well positioned to rapidly advance our immune tolerance pipeline, including the lead program SEL-212, the first non-immunogenic treatment for refractory and tophaceous gout,” said Werner Cautreels, PhD, President and CEO at Selecta. “Severe gout is a highly debilitating disease and just one of the potential therapeutic applications of our proprietary Synthetic Vaccine Particle (SVP) platform. With a well established development path and favorable pro forma economics, SEL-212 is a great opportunity. SEL-212 is just the beginning for us, as we have identified many biopharmaceuticals, including existing and new classes of biologics such as gene therapy, where the effects of anti-drug antibodies are deleterious.”

Selecta has established strong R&D and manufacturing expertise to enable the company to readily adapt its proprietary SVP platform to other applications developed internally or in collaboration with partners. In addition to its lead program for severe gout (SEL-212), Selecta is advancing immune tolerance programs to prevent anti-drug antibodies (ADA) against Factor VIII (SEL-201), anti-TNF alpha antibodies, and vectors used for gene therapy as well as candidates for allergies and auto-immune diseases.

Including the more than \\$20 million announced today, Selecta has obtained a total of \\$78.6 Million in private equity funding to date. Selecta is backed by top-tier venture investors, including Polaris Venture Partners, Flagship Ventures, OrbiMed Advisors, NanoDimension, Rusnano, I2BF, Eminent Venture Capital and Leukon Investments.